Rotavirus is a contagious disease majorly affecting children and infants; watery diarrhea, vomiting, fever, and abdominal pain are some major symptoms witnessed by doctors.
|Market||Rotavirus Vaccine Market|
|Analysis Period||2017 - 2028|
|Forecast Data||2021 - 2028|
|Segments Covered||By Type, By End User, and By Region|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||BIOVIRx Inc, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Bharat Biotech, Biological E, Bio Farma, Novartis AG, GlaxoSmithKline plc., Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd, Berghofer Medical Research Institute, and Pfizer, Inc.|
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
|Customization Scope||10 hrs of free customization and expert consultation|
Noticeable increase in number of patients suffering from various infections is resulting in government focus towards creating awareness among consumers related to available medications. Infection such as rotavirus has been impacting the lives of infants & children’s across the globe. Countries with poor resources are witnessing high death ratio. The mortality due to rotavirus across the globe is 600,000 each year and 80% of these deaths occur in less developed and poor countries. Rotavirus gastroenteritis results in only 20 to 70 childhood deaths per year in the United States. Rapid technological advancements in healthcare sector, increasing number of clinical trials by major players for development of new vaccines and increasing government spending on increasing the awareness among consumers are major factors expected to drive the growth of global rotavirus vaccine market. Major players are investing high for the development of new vaccines. Their approach towards decline the child hospitalization rate and lower the cost spent of rotavirus hospitalization. From 2007-2011 on an average annually 280,000 clinic visits, 62,000 emergency department visits, and 45,000 hospitalizations for rotavirus disease were seen in the US of children younger than age 5 years.
Players are focused on enhancing the business through new product launches and acquisitions. Their approach towards securing long time contracts in order to enhance the revenue share are factors expected to impact the growth of rotavirus vaccine market. In 2021, GSK a global drugs manufacturer signed a contract with UNICEF to supply its rotavirus vaccine, Rotarix, through the Humanitarian Mechanism for civil society organizations serving the vaccination needs of refugee and other emergency situations. In 2021, Bharat Biotech, a global drug developer received award “BioSpectrum Product of the Year Award 2020” for its rotavirus vaccine, “ROTAVAC 5D”. The vaccine is safe and effective in the prevention of rotavirus diarrhea. This is expected to help company attract new customers and increase product sale. Factors such as high cost associated to vaccine development and strict government regulations related to product approval are factors expected to hamper the growth of global rotavirus vaccine market. The drug regulatory bodies are implementing stringent regulations for the approval of drugs. In 2010, The US Food and Drug Administration (FDA), in public meeting advised healthcare practitioners to temporarily stop using of GlaxoSmithKline's (GSK's) Rotarix rotavirus vaccine. The vaccine has presence of porcine circovirus 1 (PCV1) in the product which is harmful. In addition, high price of vaccine for the low economic growth countries is expected to challenge the growth of rotavirus vaccine market. However, increasing investment for drug development from major players and development of low cost vaccines are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing partnership and contract between private and public enterprises is expected to support the revenue transaction of target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global rotavirus vaccine market due to wide adoption of the vaccines from consumers. In addition, availability of advanced R&D infrastructure in the country and high government spending on development of healthcare sector are factors expected to support the growth of target market. Standard healthcare regulatory scenario, rising awareness activities and implementation of various vaccination programs by the government is expected to impact the growth of regional market.
The global rotavirus vaccine market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Rotavirus Vaccine Market Segment Analysis, 2020
The global rotavirus vaccine market is segmented into type, and end use. The type segment is divided into Lanzhou Lamb, Rotarix, Rotavac, Rotavin-M1, and others. The end use segment is bifurcated into hospitals, clinics, and academic & research lab. Among end use the hospital segment is expected to account for major revenue share in the global market. Players operating in the global rotavirus vaccine market are BIOVIRx Inc, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Bharat Biotech, Biological E, Bio Farma, Novartis AG, GlaxoSmithKline plc., Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd, Berghofer Medical Research Institute, and Pfizer, Inc.
Market By Type
Market By End Use
Academic & Research Lab
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Rapid technological advancements in healthcare sector, increasing number of clinical trials by major players for development of new vaccines and increasing government spending on increasing the awareness among consumers are major factors expected to drive the growth of global market.
In type the Rotarix segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Bharat Biotech, Biological E, Bio Farma, Novartis AG, GlaxoSmithKline plc., Sanofi, and Lanzhou Institute of Biologicals Products Co., Ltd.
The North America is expected to account for major revenue share in the global market.
Factors such as high cost associated to vaccine development and strict government regulations related to product approval are factors expected to hamper the growth of global market.